Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Myron S. Cohen is active.

Publication


Featured researches published by Myron S. Cohen.


The New England Journal of Medicine | 2011

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

Myron S. Cohen; Ying Q. Chen; Marybeth McCauley; Theresa Gamble; Mina C. Hosseinipour; Nagalingeswaran Kumarasamy; James Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Sheela Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno Santos; Kenneth H. Mayer; Irving Hoffman; Susan H. Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A. Mills; Guy de Bruyn; Ian Sanne; Joseph J. Eron; Joel E. Gallant; Diane V. Havlir; Susan Swindells; Heather J. Ribaudo; Vanessa Elharrar; David N. Burns; Taha E. Taha

BACKGROUND Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. METHODS In nine countries, we enrolled 1763 couples in which one partner was HIV-1-positive and the other was HIV-1-negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1-infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1-related symptoms (delayed therapy). The primary prevention end point was linked HIV-1 transmission in HIV-1-negative partners. The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death. RESULTS As of February 21, 2011, a total of 39 HIV-1 transmissions were observed (incidence rate, 1.2 per 100 person-years; 95% confidence interval [CI], 0.9 to 1.7); of these, 28 were virologically linked to the infected partner (incidence rate, 0.9 per 100 person-years, 95% CI, 0.6 to 1.3). Of the 28 linked transmissions, only 1 occurred in the early-therapy group (hazard ratio, 0.04; 95% CI, 0.01 to 0.27; P<0.001). Subjects receiving early therapy had fewer treatment end points (hazard ratio, 0.59; 95% CI, 0.40 to 0.88; P=0.01). CONCLUSIONS The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 052 ClinicalTrials.gov number, NCT00074581.).


Proceedings of the National Academy of Sciences of the United States of America | 2008

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Brandon F. Keele; Elena E. Giorgi; Jesus F. Salazar-Gonzalez; Julie M. Decker; Kimmy T. Pham; Maria G. Salazar; Chuanxi Sun; Truman Grayson; Shuyi Wang; Hui Li; Xiping Wei; Chunlai Jiang; Jennifer L. Kirchherr; Feng Gao; Jeffery A. Anderson; Li Hua Ping; Ronald Swanstrom; Georgia D. Tomaras; William A. Blattner; Paul A. Goepfert; J. Michael Kilby; Michael S. Saag; Eric Delwart; Michael P. Busch; Myron S. Cohen; David C. Montefiori; Barton F. Haynes; Brian Gaschen; Gayathri Athreya; Ha Y. Lee

The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for productive clinical infection could be instrumental in elucidating the molecular basis of HIV-1 transmission and in designing effective vaccines. Here, we developed a mathematical model of random viral evolution and, together with phylogenetic tree construction, used it to analyze 3,449 complete env sequences derived by single genome amplification from 102 subjects with acute HIV-1 (clade B) infection. Viral env genes evolving from individual transmitted or founder viruses generally exhibited a Poisson distribution of mutations and star-like phylogeny, which coalesced to an inferred consensus sequence at or near the estimated time of virus transmission. Overall, 78 of 102 subjects had evidence of productive clinical infection by a single virus, and 24 others had evidence of productive clinical infection by a minimum of two to five viruses. Phenotypic analysis of transmitted or early founder Envs revealed a consistent pattern of CCR5 dependence, masking of coreceptor binding regions, and equivalent or modestly enhanced resistance to the fusion inhibitor T1249 and broadly neutralizing antibodies compared with Envs from chronically infected subjects. Low multiplicity infection and limited viral evolution preceding peak viremia suggest a finite window of potential vulnerability of HIV-1 to vaccine-elicited immune responses, although phenotypic properties of transmitted Envs pose a formidable defense.


The New England Journal of Medicine | 1997

Sexual transmission of HIV

Rachel A. Royce; Arlene C. Seña; Willard Cates; Myron S. Cohen

This article focuses on the epidemiology and biology of the host-related factors that affect the sexual transmission of HIV. It discusses host susceptibility and infectiousness environment biologic agent and preventing sexually transmitted HIV infection.


The Lancet | 1997

Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1

Myron S. Cohen; Irving Hoffman; Rachel A. Royce; Peter N. Kazembe; John R. Dyer; Celine Costello Daly; Dick Zimba; Pietro Vernazza; Martin Maida; Susan A. Fiscus; Joseph J. Eron

BACKGROUND Transmission of HIV-1 is predominantly by heterosexual contact in sub-Saharan Africa, where sexually transmitted diseases (STDs) are also common. Epidemiological studies suggest that STDs facilitate transmission of HIV-1, but the biological mechanism remains unclear. We investigated the hypothesis that STDs increase the likelihood of transmission of HIV-1 through increased concentration of the virus in semen. METHODS HIV-1 RNA concentrations were measured in seminal and blood plasma from 135 HIV-1-seropositive men in Malawi; 86 had urethritis and 49 controls did not have urethritis. Men with urethritis received antibiotic treatment according to the guidelines of the Malawian STD Advisory Committee. Samples were analysed at baseline and at week 1 and week 2 after antibiotic therapy in urethritis patients, and at baseline and week 2 in the control group. FINDINGS HIV-1-seropositive men with urethritis had HIV-1 RNA concentrations in seminal plasma eight times higher than those in seropositive men without urethritis (12.4 vs 1.51 x 10(4) copies/mL, p = 0.035), despite similar CD4 counts and concentrations of blood plasma viral RNA. Gonorrhoea was associated with the greatest concentration of HIV-1 in semen (15.8 x 10(4) copies/mL). After the urethritis patients received antimicrobial therapy directed against STDs, the concentration of HIV-1 RNA in semen decreased significantly (from 12.4 x 10(4) copies/mL to 8.91 x 10(4) copies/mL at 1 week [p = 0.03] and 4.12 x 10(4) copies/mL at 2 weeks [p = 0.0001]). Blood plasma viral RNA concentrations did not change. There was no significant change in seminal plasma HIV-1 RNA concentrations during the 2-week period in the control group (p = 0.421). INTERPRETATION These results suggest that urethritis increases the infectiousness of men with HIV-1 infection. HIV-1-control programmes, which include detection and treatment of STDs in patients already infected with HIV-1, may help to curb the epidemic. Targeting of gonococcal urethritis may be a particularly effective strategy.


The Journal of Infectious Diseases | 2004

Brief but Efficient: Acute HIV Infection and the Sexual Transmission of HIV

Christopher D. Pilcher; Hsiao Chuan Tien; Joseph J. Eron; Pietro Vernazza; Szu Yun Leu; Paul W. Stewart; Li Ean Goh; Myron S. Cohen

BACKGROUND We examined whether viral dynamics in the genital tract during the natural history of acute human immunodeficiency virus type 1 (HIV-1) infection could explain efficient heterosexual transmission of HIV. METHODS We measured HIV-1 concentration in blood and semen samples from patients with acute and long-term HIV-1 infection. We explored the effect of changes in viral dynamics in semen on the probability of transmission per coital act, using a probabilistic model published elsewhere. RESULTS Considered over time from infection, semen HIV-1 concentrations, in men with acute infection, increase and decrease in approximate parallel with changes occurring in blood. Modeling suggests that these acute dynamics alone are sufficient to increase probability of heterosexual transmission by 8-10-fold between peak (day 20 after infection, based on the model) and virologic set points (day 54 and later after infection). Depending on the frequency of coitus, men with average semen HIV-1 loads and without sexually transmitted diseases (STDs) would be expected to infect 7%-24% of susceptible female sex partners during the first 2 months of infection. The predicted infection rate would be much higher when either partner has an STD. CONCLUSIONS Empirical biological data strongly support the hypothesis that sexual transmission by acutely infected individuals has a disproportionate effect on the spread of HIV-1 infection. Acute hyperinfectiousness may, in part, explain the current pandemic in heterosexual individuals.


Nature | 2013

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Hua-Xin Liao; Rebecca M. Lynch; Tongqing Zhou; Feng Gao; S. Munir Alam; Scott D. Boyd; Andrew Fire; Krishna M. Roskin; Chaim A. Schramm; Z. F. Zhang; Jiang Zhu; Lawrence Shapiro; Nisc Comparative Sequencing Program; James C. Mullikin; S. Gnanakaran; Peter Hraber; Kevin Wiehe; Garnett Kelsoe; Guang Yang; Shi-Mao Xia; David C. Montefiori; Robert Parks; Krissey E. Lloyd; Richard M. Scearce; Kelly A. Soderberg; Myron S. Cohen; Gift Kamanga; Mark K. Louder; Lillian Tran; Yue Chen

Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint for effective vaccination. Here we report the isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection. The mature antibody, CH103, neutralized approximately 55% of HIV-1 isolates, and its co-crystal structure with the HIV-1 envelope protein gp120 revealed a new loop-based mechanism of CD4-binding-site recognition. Virus and antibody gene sequencing revealed concomitant virus evolution and antibody maturation. Notably, the unmutated common ancestor of the CH103 lineage avidly bound the transmitted/founder HIV-1 envelope glycoprotein, and evolution of antibody neutralization breadth was preceded by extensive viral diversification in and near the CH103 epitope. These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination.


Journal of Experimental Medicine | 2009

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Jesus F. Salazar-Gonzalez; Maria G. Salazar; Brandon F. Keele; Gerald H. Learn; Elena E. Giorgi; Hui Li; Julie M. Decker; Shuyi Wang; Joshua Baalwa; Matthias H. Kraus; Nicholas F. Parrish; Katharina S. Shaw; M. Brad Guffey; Katharine J. Bar; Katie L. Davis; Christina Ochsenbauer-Jambor; John C. Kappes; Michael S. Saag; Myron S. Cohen; Joseph Mulenga; Cynthia A. Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S. Perelson; Tanmoy Bhattacharya; Barton F. Haynes; Bette T. Korber; Beatrice H. Hahn

Identification of full-length transmitted HIV-1 genomes could be instrumental in HIV-1 pathogenesis, microbicide, and vaccine research by enabling the direct analysis of those viruses actually responsible for productive clinical infection. We show in 12 acutely infected subjects (9 clade B and 3 clade C) that complete HIV-1 genomes of transmitted/founder viruses can be inferred by single genome amplification and sequencing of plasma virion RNA. This allowed for the molecular cloning and biological analysis of transmitted/founder viruses and a comprehensive genome-wide assessment of the genetic imprint left on the evolving virus quasispecies by a composite of host selection pressures. Transmitted viruses encoded intact canonical genes (gag-pol-vif-vpr-tat-rev-vpu-env-nef) and replicated efficiently in primary human CD4+ T lymphocytes but much less so in monocyte-derived macrophages. Transmitted viruses were CD4 and CCR5 tropic and demonstrated concealment of coreceptor binding surfaces of the envelope bridging sheet and variable loop 3. 2 mo after infection, transmitted/founder viruses in three subjects were nearly completely replaced by viruses differing at two to five highly selected genomic loci; by 12–20 mo, viruses exhibited concentrated mutations at 17–34 discrete locations. These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses.


Journal of Experimental Medicine | 2009

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

Nilu Goonetilleke; Michael K. P. Liu; Jesus F. Salazar-Gonzalez; Guido Ferrari; Elena E. Giorgi; Vitaly V. Ganusov; Brandon F. Keele; Gerald H. Learn; Emma L. Turnbull; Maria G. Salazar; Kent J. Weinhold; Stephen Moore; Norman L. Letvin; Barton F. Haynes; Myron S. Cohen; Peter Hraber; Tanmoy Bhattacharya; Persephone Borrow; Alan S. Perelson; Beatrice H. Hahn; George M. Shaw; Bette T. Korber; Andrew J. McMichael

Identification of the transmitted/founder virus makes possible, for the first time, a genome-wide analysis of host immune responses against the infecting HIV-1 proteome. A complete dissection was made of the primary HIV-1–specific T cell response induced in three acutely infected patients. Cellular assays, together with new algorithms which identify sites of positive selection in the virus genome, showed that primary HIV-1–specific T cells rapidly select escape mutations concurrent with falling virus load in acute infection. Kinetic analysis and mathematical modeling of virus immune escape showed that the contribution of CD8 T cell–mediated killing of productively infected cells was earlier and much greater than previously recognized and that it contributed to the initial decline of plasma virus in acute infection. After virus escape, these first T cell responses often rapidly waned, leaving or being succeeded by T cell responses to epitopes which escaped more slowly or were invariant. These latter responses are likely to be important in maintaining the already established virus set point. In addition to mutations selected by T cells, there were other selected regions that accrued mutations more gradually but were not associated with a T cell response. These included clusters of mutations in envelope that were targeted by NAbs, a few isolated sites that reverted to the consensus sequence, and bystander mutations in linkage with T cell–driven escape.


Nature Reviews Microbiology | 2004

The role of sexually transmitted diseases in HIV transmission

Shannon Galvin; Myron S. Cohen

More than 42 million people worldwide are now infected with HIV, in spite of sustained prevention activities. Although the spread of HIV has been primarily sexual, epidemiological studies have indicated that the efficiency of the spread of HIV is poor, perhaps as infrequently as 1 in every 1,000 episodes of sexual intercourse. However, sexually transmitted diseases (STDs) that cause ulcers or inflammation greatly increase the efficiency of HIV transmission — by increasing both the infectiousness of, and the susceptibility to HIV infection. STDs might be particularly important in the early stages of a localized HIV epidemic, when people with risky sexual behaviour are most likely to become infected. In China, eastern Europe and Russia, there has been a remarkable increase in the incidence of STDs in recent years, and this is reflected in the rapid increase in the spread of HIV in these areas. Targeted STD detection and treatment should have a central role in HIV prevention in these emerging epidemics.


The Lancet | 1998

Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis

Myron S. Cohen

In this article a causal link between HIV-1 transmission and classic sexually transmitted diseases (STDs) has been demonstrated. It discusses the biology of HIV-1 transmission and presents in-vitro and clinical studies that show that STDs enhance HIV transmission.

Collaboration


Dive into the Myron S. Cohen's collaboration.

Top Co-Authors

Avatar

Irving Hoffman

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joseph J. Eron

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Susan A. Fiscus

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Angela D. M. Kashuba

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bradley E. Britigan

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Marcia M. Hobbs

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francis Martinson

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge